Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia - sprookjes - yvandenbroek - TriplyDB

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

http://www.wikidata.org/entity/Q33424963

about

Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection Direct-acting antivirals for chronic hepatitis C.Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6.Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine Real world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.NS5A inhibitors for the treatment of hepatitis C infection.Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.Direct-acting antivirals for chronic hepatitis C Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis

P2860

Q33440130-00D882EB-A8C3-47EA-B637-B850B94D9487 Q34557595-60AC6589-CC0F-491E-A020-010A15601042 Q37040485-E726644C-1A80-40F8-8BEC-5575BA8FC089 Q37287684-1108EC77-06B8-4F2D-B50C-02B33A49CA48 Q38620762-BD4B8B82-096E-4551-A4AB-A8740F392309 Q39031350-D6DE90B2-8188-4E2A-8050-07495D22C319 Q39675766-754A066A-6228-4B53-9FF5-63F26B5157E7 Q40409263-E1B7F1E5-E930-4A12-95B9-9450302469FA Q57389418-BC607760-2CE8-41CE-826D-016B971B962C Q58714957-C9D94C86-0E7F-4059-B5F4-8386DC740A87

P2860

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

http://www.wikidata.org/entity/Q33424963

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Ombitasvir/paritaprevir/r, das ...... ytopaenia and hypoalbuminaemia

@ast

Ombitasvir/paritaprevir/r, das ...... ytopaenia and hypoalbuminaemia

@en

type

label

Ombitasvir/paritaprevir/r, das ...... ytopaenia and hypoalbuminaemia

@ast

Ombitasvir/paritaprevir/r, das ...... ytopaenia and hypoalbuminaemia

@en

prefLabel

Ombitasvir/paritaprevir/r, das ...... ytopaenia and hypoalbuminaemia

@ast

Ombitasvir/paritaprevir/r, das ...... ytopaenia and hypoalbuminaemia

@en

P1433

Q33424963-F63BE77D-DEF6-451F-ABC3-172B46CAF4E8

P1476

Q33424963-99661298-D14A-47B8-9695-4D7FF73B994F

P2093

Q33424963-0E43AE70-4D05-4BF1-A4D0-9CE9A828BA10

Q33424963-25F85AD7-266E-4BA4-AEFC-57292575E2A2

Q33424963-4C713117-49B9-4FEC-A1ED-CD7BE269827C

Q33424963-5A5496F5-43A0-4E9B-A2AB-7E19C95F8E7D

Q33424963-737396A8-A99A-4A9E-839C-996F4275782C

Q33424963-8D1A9D83-92DF-4A3B-AF27-5860D00C4C78

Q33424963-C7B708B0-644E-41FF-9F45-CD69A79791D1

Q33424963-C9F825B6-AE6D-4E8C-8ED4-02CEE9127636

Q33424963-CE39502C-CB9D-4EF8-89B5-8844B1BB2A5F

Q33424963-ED6D3F5E-88D7-464A-AC0B-1D5C9A935C99

P2860

Q33424963-0CEEC93E-D8D9-4CA3-9A69-8ACB77571BD7

Q33424963-10E7AF54-FCCD-4401-AAC7-0A4C67D7B275

Q33424963-28D1CB96-0232-4822-82A4-F5E4E040C139

Q33424963-3C1AD204-6481-47DA-B645-85D6FEE3D233

Q33424963-44EB8106-2DC4-40CB-BD4D-90C52913BF6F

Q33424963-4C5E8D11-2FE1-470E-A5A7-5019EBEEA31F

Q33424963-9623A4D8-97A8-4745-955D-08BF20D0B0FB

Q33424963-9D0B566C-833A-4E60-84CD-62D5052880FB

Q33424963-A8569D17-4D1D-44DA-A111-F943FB8B5C9C

Q33424963-AA5354D1-1921-4382-AF65-1415B42026EF

P304

Q33424963-55418A41-CA40-4CCA-BEE8-8EF1A9B39468

P31

Q33424963-5D596A9E-96F1-4867-8471-440EEADE5B3C

P356

Q33424963-F3C3AB52-4147-4E96-BD6C-FD39FCA205D8

P433

Q33424963-3AA283B4-D968-4022-954E-F75095233CA0

P478

Q33424963-9370EAB2-35F9-4619-8312-4790408E5F07

P50

Q33424963-9834080A-85C6-41EA-926A-C457C3ABD54D

P577

Q33424963-1D703E27-9F22-4A5E-811D-C327B52FFEC8

P698

Q33424963-EEBB7B9F-9DD1-446B-B4B7-7F59170E25CA

P921

Q33424963-9BFA6751-78BD-468C-AFB8-085323122786

Q33424963-F69A0ED6-49E7-447A-8CE9-872AEEAC4ED1

P932

Q33424963-F1CC1DA8-AFD8-4AE6-A54D-8B6B86B0A64C

P356

P1433

Liver International

P1476

Ombitasvir/paritaprevir/r, das ...... ytopaenia and hypoalbuminaemia

@en

P2093

Gregory Everson

http://www.w3.org/2001/XMLSchema#string

Heiner Wedemeyer

http://www.w3.org/2001/XMLSchema#string

Juan Carlos Lopez-Talavera

http://www.w3.org/2001/XMLSchema#string

Marcos Pedrosa

http://www.w3.org/2001/XMLSchema#string

Marina Berenguer

http://www.w3.org/2001/XMLSchema#string

Michael W Fried

http://www.w3.org/2001/XMLSchema#string

Mitchell L Shiffman

http://www.w3.org/2001/XMLSchema#string

Peter Ferenci

http://www.w3.org/2001/XMLSchema#string

Roger Trinh

http://www.w3.org/2001/XMLSchema#string

Sandra Lovell

http://www.w3.org/2001/XMLSchema#string

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

Telaprevir for retreatment of HCV infection

Telaprevir for previously untreated chronic hepatitis C virus infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

P304

2358-2362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.12931

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26248955

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia

P932

5049489

http://www.w3.org/2001/XMLSchema#string